Updated on 2026/06/22

写真a

 
Heiichiro Hamada
 
Organization
University Hospital, Medical and Dental Sciences Area University Hospital Clinical Facilities Division of Blood Transfusion Medicine and Cell Therapy Assistant Professor
Title
Assistant Professor
Degree
(1994.3 Oita Medical University)

Research Interests

  • 細胞治療

  • 貯血

  • 膠原病1

  • リンパ腫

  • 白血病

  • 血液内科

Research Areas

輸血・細胞治療領域, 血液・膠原病内科領域

Research History

  • 2014.4    Kagoshima University   Assistant Professor

Professional Memberships

  • 2015.10    日本血液学会

  • 1995.5    日本内科学会

Qualification acquired

  • Doctor

 

Papers

  • Furukawa Y, Hamada H, Kamikawaji K, Unoki T, Inoue H, Tashiro Y, Okamoto M, Baba M, Hashiguchi T .  Successful treatment of an AIDS patient with prolonged Mycobacterium avium bacteremia, high HIV RNA, HBV infection, Kaposi's sarcoma and cytomegalovirus retinitis. .  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy26 ( 2 ) 279 - 281   2020.2

    　More details

  • Nakamura D, Ueno T, Nakabeppu SI, Shyodai A, Arima N, Kamada Y, Hamada HI, Suzuki S, Yoshimitsu M, Ishitsuka K .  Validation of prognostic indices in adult T-cell leukemia/lymphoma and their prognostic value at the start of second-line treatment. .  Leukemia & lymphoma67 ( 7 ) 1520 - 1526   2026.6

    　More details

    Language：English  

    DOI： 10.1080/10428194.2026.2645946

    PubMed

  • Arai A, Yoshimitsu M, Otsuka M, Ito Y, Miyazono T, Nakano N, Obama K, Nakashima H, Hanada S, Owatari S, Nakamura D, Tokunaga M, Kamada Y, Utsunomiya A, Haraguchi K, Hayashida M, Fujino S, Odawara J, Tabuchi T, Suzuki S, Hamada H, Kawamoto Y, Uchida Y, Hachiman M, Ishitsuka K .  Identification of putative noncanonical driver mutations in patients with essential thrombocythemia. .  European journal of haematology110 ( 6 ) 639 - 647   2023.6

    　More details

    Language：English   Publisher：Wiley  

    <jats:title>Abstract</jats:title><jats:p>Essential thrombocythemia (ET) cases without canonical <jats:italic>JAK2</jats:italic>, <jats:italic>CALR</jats:italic>, or <jats:italic>MPL</jats:italic> mutations, that is, triple‐negative (TN) ET, have been found in 10%–20% of ET cases. Owing to the limited number of TN ET cases, its clinical significance remains unclear. This study evaluated TN ET's clinical characteristics and identified novel driver mutations. Among 119 patients with ET, 20 (16.8%) had no canonical <jats:italic>JAK2/CALR/MPL</jats:italic> mutations. Patients with TN ET tended to be younger and had lower white blood cell counts and lactate dehydrogenase values. We identified putative driver mutations in 7 (35%): <jats:italic>MPL</jats:italic> S204P, <jats:italic>MPL</jats:italic> L265F, <jats:italic>JAK2</jats:italic> R683G, and <jats:italic>JAK2</jats:italic> T875N were previously reported as candidate driver mutations in ET. Moreover, we identified a <jats:italic>THPO</jats:italic> splicing site mutation, <jats:italic>MPL</jats:italic>*636Wext*12, and <jats:italic>MPL</jats:italic> E237K. Four of the seven identified driver mutations were germline. Functional studies on <jats:italic>MPL</jats:italic>*636Wext*12 and <jats:italic>MPL</jats:italic> E237K revealed that they are gain‐of‐function mutants that increase MPL signaling and confer thrombopoietin hypersensitivity with very low efficiency. Patients with TN ET tended to be younger, although this was thought to be due to the inclusion of germline mutations, hereditary thrombocytosis. Accumulating the genetic and clinical characteristics of noncanonical mutations may help future clinical interventions in TN ET and hereditary thrombocytosis.</jats:p>

    DOI： 10.1111/ejh.13945

    PubMed

    CiNii Research